Nuvo Research Inc., a specialty pharmaceutical company and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A., today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Pliaglis is a topical local anesthetic cream that uses Nuvo's proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. Pliaglis is indicated for use on intact skin in adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal. Pliaglis was brought back to the market in the U.S. after the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application in October 2012 filed by Galderma.
"The introduction of Pliaglis marks the next step of Galderma's growth in the aesthetic & corrective area," said Francois Fournier, President of U.S. and Canada for Galderma Laboratories, L.P. "Galderma is more than ever committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals." "We are excited to announce the U.S. launch of Pliaglis by our partner Galderma," said Dr. Bradley Galer, President of Nuvo's Pain Group.
"Pliaglis' efficacy, safety, rapid onset of action and ease of use promises to greatly improve the experience of patients by providing analgesia while they are undergoing superficial dermatologic and cosmetic procedures."